High Clinical Impact: Neoadjuvant Synergy in Merkel Cell Carcinoma
Highlights
The primary results of this investigator-initiated Phase II trial highlight three critical findings for the management of Merkel cell carcinoma (MCC):
1. A pathological complete response (pCR) rate of 57.7% was achieved with only six weeks of neoadjuvant lenvatinib and pembrolizumab.
2. The objective response rate (ORR) among radiographically evaluable patients reached 72.7%.
3. Progression-free survival (PFS) demonstrated a significant correlation with radiographic response, with a median PFS not yet reached at 20 months.
